Patients on dialysis are more likely to be treated for prostate cancer compared with patients not on dialysis and kidney transplant recipients, investigators reported at the American Society of Nephrology’s Kidney Week 2022 conference in Orlando, Florida.
Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, Nagaraju Sarabu, MD, of University Hospitals in Cleveland, Ohio, and colleagues studied 272 men with low-risk prostate cancer: 42 patients on dialysis, 20 kidney transplant recipients, and 210 patients without end-stage kidney disease (ESKD).
The non-ESKD group had significant 73% decreased odds of curative treatment compared with the dialysis group, the investigators reported in a poster presentation. None of the kidney transplant recipients died from prostate cancer.
“Dialysis patients, who are more likely to die of other causes, are paradoxically more likely to be treated for low-risk prostate cancer,” the authors concluded. “Active surveillance should be performed in this population, and should not preclude transplant eligibility.”
Dr Sarabu’s group noted that men with ESKD being evaluated for kidney transplantation are screened for prostate cancer, and when a cancer is found, it often is treated because of concerns about transplant eligibility in the presence of malignancy.
Sarabu N, Dong W, Koroukian SM. Treatment patterns for low-risk prostate cancer in dialysis, kidney transplant, and non-dialysis. Presented at: Kidney Week 2022; November 3-6, Orlando, Florida. Abstract SA-PO143.
This article originally appeared on Renal and Urology News